Fox Chase SCID® Mutant Mice

Nomenclature:

• US Stocks/Strains:
  • BALB/cJHan™Hsd-Prkdc^scid
  • HsdIcr:Ha(ICR)-Prkdc^scid
  • C3H.C-Prkdc^scid/IcrSmnHsd
  • C.B-17/IcrHsd-Prkdc^scid
• EU Stocks/Strains:
  • BALB/cJHan™Hsd-Prkdc^scid
  • C.B-17/IcrHsd-Prkdc^scid
  • C.B-17/IcrHan™Hsd-Prkdc^scid

Fox Chase SCID Origin

• Harlan acquired the Fox Chase SCID from the Fox Chase Cancer Center, Philadelphia, Pennsylvania, in 1991.

 Fox Chase SCID Characteristics

• Coat: Albino
• Severe combined immunodeficiency due to Prkdc^scid autosomal recessive, single nucleotide polymorphism on chromosome 16
• T-lymphocyte deficiency
• B-lymphocyte deficiency
• Natural Killer (NK) cell, macrophage, and granulocyte cell numbers and function are normal
• As SCID^® mice age, a variable percentage become “leaky” from the spontaneous development of functional T and B lymphocytes
• Highly susceptible to opportunistic viral and bacterial infection

Fox Chase SCID Research Use

• Oncology
• Transplantation
• Tumor cell growth
• Immunology

Harlan Laboratories' Production

We maintain on the following diets:

• US Stock:  Teklad Global Diet 2018S 
• EU Stock/Strain:  Teklad Global Diet 2019S 

Maintained within Harlan Isotec flexible-film isolators

FOX CHASE SCID^® is a registered trademark of Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.